Encompass Health (NYSE:EHC) PT Raised to $108.00

Encompass Health (NYSE:EHC) had its price target increased by Truist Financial from $104.00 to $108.00 in a report published on Monday, Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a report on Wednesday, July 10th. Barclays lowered their price target on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Leerink Partners initiated coverage on shares of Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price objective on the stock. Stephens reiterated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Finally, KeyCorp began coverage on Encompass Health in a research note on Friday, October 11th. They issued an “overweight” rating and a $115.00 price target on the stock. Eight analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health currently has an average rating of “Buy” and an average target price of $104.67.

Encompass Health Stock Down 0.5 %

Shares of NYSE EHC opened at $96.90 on Monday. The firm has a fifty day simple moving average of $92.62 and a two-hundred day simple moving average of $87.67. The firm has a market capitalization of $9.76 billion, a PE ratio of 26.19, a price-to-earnings-growth ratio of 1.43 and a beta of 0.88. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.08. Encompass Health has a 12 month low of $57.55 and a 12 month high of $98.74.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, August 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.01 by $0.10. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. Encompass Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $0.95 earnings per share. Equities analysts expect that Encompass Health will post 4.18 earnings per share for the current year.

Encompass Health announced that its Board of Directors has initiated a share repurchase plan on Wednesday, July 24th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 5.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Encompass Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st were issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.70%. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. The ex-dividend date was Tuesday, October 1st. Encompass Health’s dividend payout ratio (DPR) is presently 18.38%.

Insiders Place Their Bets

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Encompass Health

Institutional investors have recently made changes to their positions in the business. V Square Quantitative Management LLC increased its holdings in Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the last quarter. Creative Planning boosted its stake in shares of Encompass Health by 4.1% during the 3rd quarter. Creative Planning now owns 19,086 shares of the company’s stock worth $1,844,000 after acquiring an additional 743 shares during the last quarter. Oliver Luxxe Assets LLC increased its stake in shares of Encompass Health by 43.7% in the 3rd quarter. Oliver Luxxe Assets LLC now owns 60,553 shares of the company’s stock worth $5,852,000 after purchasing an additional 18,407 shares in the last quarter. CHICAGO TRUST Co NA bought a new position in Encompass Health in the 3rd quarter worth $221,000. Finally, Reinhart Partners LLC. raised its holdings in Encompass Health by 2.4% in the 3rd quarter. Reinhart Partners LLC. now owns 673,040 shares of the company’s stock worth $65,043,000 after purchasing an additional 15,550 shares during the period. Institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.